article thumbnail

Hospital Universitario and Josep Carreras develop cell therapy for leukaemia

Pharmaceutical Technology

Spain’s Hospital Universitario 12 de Octubre researchers, along with the Josep Carreras Leukaemia Research Institute, have developed a new cell therapy based on STAb cells to treat a type of leukaemia. The post Hospital Universitario and Josep Carreras develop cell therapy for leukaemia appeared first on Pharmaceutical Technology.

Hospitals 110
article thumbnail

Perioperative pembrolizumab improves outcomes in early-stage NSCLC

Hospital Pharmacy Europe

A perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition with pembrolizumab significantly improves disease outcomes for patients with early-stage non-small-cell lung cancer (NSCLC), according to the findings of a trial by an international research group.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Innovative combination treatment significantly improves survival in pleural mesothelioma

Hospital Pharmacy Europe

Adding an arginine-depleting agent to chemotherapy extends survival for patients with advanced non-epithelial pleural mesothelioma, a randomised controlled trial suggests. Pegargiminase-based chemotherapy was well tolerated, with no new safety signals, they added. mg/ m2) or placebo. mg/ m2) or placebo.

article thumbnail

Serplulimab increases survival in small cell lung cancer patients

European Pharmaceutical Review

A Phase III trial from Shanghai Henlius Biotech is the first study to suggest that the programmed cell death (PD) 1 receptor immune checkpoint inhibitor Hansizhuang (serplulimab) plus chemotherapy can markedly improve survival for extensive-stage small cell lung cancer (ES-SCLC) patients. A follow-up after 12.3 months).

article thumbnail

EMA grants mitazalimab orphan drug designation for pancreatic cancer

Hospital Pharmacy Europe

A human CD40 agonistic antibody targeting CD40, mitazalimab kickstarts the cancer-immunity cycle by priming and activating tumour-specific T cells. Targeting CD40 with mitazalimab has the potential to augment responses to chemotherapy. A median duration of response of 8.7 months was also reported.

article thumbnail

ESMO: TIL therapy improves on Yervoy in melanoma trial

pharmaphorum

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

article thumbnail

The GoCART Coalition: Guidance for pharmacists

Hospital Pharmacy Europe

Guidance on the provision of CAR T and cellular therapy services in hospital pharmacy has been published by the GoCART Coalition to harmonise implementation across Europe. In the last decade, immunotherapies that treat cancers using the patient’s immune system to recognise, attack and kill malignant cells have reached the market.